Glioblastoma (GBM) is a highly aggressive brain tumor characterized by its ability to evade the immune system, hindering the efficacy of current immunotherapies. Recent research has highlighted the important role of immunosuppressive macrophages in the tumor microenvironment (TME) in driving this immune evasion. In this study, we are the first to identify as a key regulator of tumor-associated macrophage (TAM)-mediated immunosuppression in GBM. We found that a high expression is associated with poor patient outcomes and increased infiltration of immune cells, particularly macrophages. Functional analyses revealed 's critical involvement in immune-related pathways, including immune response activation, mononuclear cell differentiation, and the positive regulation of cytokine production. Additionally, single-cell RNA sequencing data demonstrated that macrophages with a high expression were associated with increased phagocytosis, immune suppression, and enhanced tumor growth. These findings suggest that could serve as both a prognostic marker and a therapeutic target for enhancing anti-tumor immunity in GBM.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3390/cells14020066 | DOI Listing |
Anal Chem
January 2025
Department of Laboratory Medicine, School of Medicine, Yangtze University, Jingzhou 434023, P.R. China.
Acylaminoacyl-peptide hydrolase (APEH), a serine peptidase that belongs to the prolyl oligopeptidase (POP) family, catalyzes removal of N-terminal acetylated amino acid residues from peptides. As a key regulator of protein N-terminal acetylation, APEH was involved in many important physiological processes while its aberrant expression was correlated with progression of various diseases such as inflammation, diabetics, Alzheimer's disease (AD), and cancers. However, while emerging attention has been attracted in APEH-related disease diagnosis and drug discovery, the mechanisms behind APEH and related disease progression are still unclear; thus, further investigating the physiological role and function of APEH is of great importance.
View Article and Find Full Text PDFHIV Res Clin Pract
December 2025
Division of Infectious Diseases and Global Public Health, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, USA.
Background: HIV remains a major challenge in KwaZulu-Natal, South Africa, particularly for young women who face disproportionate risks and barriers to prevention and treatment. Most HIV cure trials, however, occur in high-income countries.
Objective: To examine the perspectives of young women diagnosed with acute HIV in a longitudinal study, focusing on their perceptions on ATI-inclusive HIV cure trials and the barriers and facilitators to participation.
Tuberculosis (Edinb)
January 2025
Infectious Bacterial Diseases Research Unit, National Animal Disease Center, Agricultural Research Service, United States Department of Agriculture, Ames, Iowa, USA.
Bovine tuberculosis is mainly caused by Mycobacterium bovis. Bacillus Calmette-Guérin (BCG) is an attenuated strain of M. bovis which provides variable disease protection.
View Article and Find Full Text PDFWest Afr J Med
September 2024
Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Background: Patient satisfaction is an essential indicator used for measuring the quality of health care delivered to a patient and contributes to strategies for the improvement of healthcare delivery. This study assessed patients' satisfaction with the quality of care at the National Health Insurance Authority (NHIA) clinic in a tertiary health facility.
Methods: The study was a descriptive cross-sectional design with 320 respondents who completed a semi-structured questionnaire.
Angiogenesis
January 2025
Department of Obstetrics and Gynaecology, Amsterdam UMC Location Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam, The Netherlands.
Adenomyosis is characterized by abnormal uterine bleeding, dysmenorrhea and subfertility. Increased expression of angiogenesis markers in adenomyosis presents a treatment opportunity and was studied in an adenomyosis mouse model. Mice were administered tamoxifen (1 mg/kg) on neonatal days 2-5.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!